Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer

Prolyl endopeptidase (PREP), also known as prolyl oligopeptidase (POP), is an Enzyme that cleaves short Peptides (<30 Amino acids in length) on the C-terminal side of proline. PREP is highly expressed in multiple carcinomas and is a potential target for Cancer therapy. A potent inhibitor of PREP, Y-29794, causes long-lasting inhibition of PREP in mouse tissues. However, there are no reports on Y-29794 effects on Cancer cell and tumor proliferation. Using cell line models of aggressive triple-negative breast Cancer (TNBC), we show here that Y-29794 inhibited proliferation and induced death in multiple TNBC cell lines. Cell death induced by Y-29794 coincided with inhibition of the IRS1-AKT-mTORC1 survival signaling pathway, although stable depletion of PREP alone was not sufficient to reduce IRS1-AKT-mTORC1 signaling or induce death. These results suggest that Y-29794 elicits its Cancer cell killing effect by targeting other mechanisms in addition to PREP. Importantly, Y-29794 inhibited tumor growth when tested in xenograft models of TNBC in mice. Induction of cell death in culture and inhibition of xenograft tumor growth support the potential utility of Y-29794 or its derivatives as a treatment option for TNBC tumors.

IRS1-AKT-mTORC1 pathway; Prolyl endopeptidase; triple-negative breast cancer.